Between Rocks and Hard Places: The Southeast Asian Pharmaceutical Industry at a Juncture - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Between Rocks and Hard Places: The Southeast Asian Pharmaceutical Industry at a Juncture

Pharmaceutical Technology

In Malaysia, Pharmaniaga, the state-backed listed company, is also facing its own set of challenges and its path is a valuable indication of regional trends affecting the industry. The undisputed leader in its home market, Pharmaniaga must go beyond its cozy protected position (Pharmaniaga being the exclusive concessionary for public hospitals sales) and step up its efforts to become a regional leader. Over the past few years, these efforts have become more visible as the company built a superb new small-volume injectables (SVI) plant to FDA standards and put a foot in China through a joint venture with a company that, such as Pharmaniaga, has public shareholders. The fact that the small-volume injectable factory (to be completed by Q4 2006) was built to FDA standards is no luck: Azhar Hussain, the company's managing director is confident that "the next stage will be registration and our ultimate goal will be to enter the US market with one or two products. Contract manufacturing is also a very serious possibility. We have no limitation as we are a generic player and competition is everywhere." Looking at the openness of his company to global cooperation, he adds that "one has to cooperate to compete nowadays."

Dynamism across the market

In the shadows of the regional leaders is a thriving lot. Medium-size companies are forcing through their market positions by developing their niche competencies and their flexibilities to be recognized as serious market contenders. Among them, Indonesia's SOHO, The Mensa Group, or Novell, Malaysia's Hovid and Kotra, Thailand's Siam pharmaceutical, Thai Nakorn Patana or Philippines United Laboratories are the best in class. With challenges lurking on every pharmaceutical horizon, these companies are using their flexibility and strong focus to design strategies that allow them to make the most out of the current situation.

Thanks to Indonesia's sheer market size, medium-size operators can have available capital to work on different approaches. The SOHO group, for instance, is completely refurbishing its production tool to bring it to the best standards in class. Tang Eng Liang, the company's president is clear about the mid-term targets: "We want to renovate our factory, to be able to export to European nations first, then, who knows, to the United States"

The quality required to achieve such results should be without any compromise, and while the emphasis is on renovating the production tool, other avenues for strengthening the business model are also sought after, as explained by SOHO Group's President Director, Andreas Djamwari: "We also have to work towards rationalizing our portfolio, by looking at consolidating therapeutic classes coverage amongst our products." As do many companies in the region, the SOHO group combines manufacturing alongside distribution activities, thus allowing the company to control its own distribution channels across Indonesia as well as to act as a distributor for any principal, local or international, willing to enter the fray. Yet, Mr. Djamwari stresses that the company is "looking for success in manufacturing instead of only distribution."

Meanwhile, external pressure cumulates on the manufacturers' shoulders across the region to comply with more stringent quality standards, face the ever-increasing bite of the international competition, notably from the dual threat of India and China, and extra difficulties are being added by local authorities and regulators. In Indonesia, a price-capping policy has been announced, although the full extent of its application is still largely unknown. Local manufacturers are willing to play the game, all the more when the future cap doesn't affect much their bottom line because they don't produce the very basic products that will see their sales prices capped off.

Roy Lembong, dynamic Director of Novell Pharmaceutical Laboratories, a versatile producer that has posted some of the best growth rates in the market, is unabated by the forthcoming price control and actually sees opportunities for some local players: "Usage of non-branded generics is low in Indonesia as there are little incentives for doctors to use them. Japan is facing the same issue but now has incentives. Doctors here still like to subscribe products from multinationals. A price capping will benefit patients, health systems as well as some players producing these type of cheap drugs."


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here